IGF2 and cancer: An exception to the above IGF-II post-translational peptidic maturation/processing is typically observed in cancer, resulting in the production of a glycosylated high-molecular-weight peptide variant, which bears additional biological advantage for cancer progression, as reviewed elsewhere [17].